Literature DB >> 24825255

Measles vaccine potency and sero-conversion rates among infants receiving measles immunization in Ilorin, Kwara State, Nigeria.

A Fowotade1, I O Okonko, C Nwabuisi, R A Bakare, A Fadeyi, F D Adu.   

Abstract

This study was designed to assess the seroconversion rate of measles vaccine among infants receiving measles immunization in Ilorin, Nigeria. The pre- and post-measles vaccination sera of the children were tested using the Haemagglutination Inhibition test. The measles vaccines administered at the immunization centre were also tested for their potency using in-vitro titration method. Only 286 (71.5%) of the vacinees returned to give post-vaccination samples. All the infants screened had low pre-vaccination measles antibody titers. Thirty one (8.0%) of the infants had measles prior to vaccination. The seroconversion pattern showed that 196 (68.6%) of the infants developed protective antibody titers. Low seroconversion rate reported in this study was due to low vaccine potency. The titers of vaccines with low potency ranged between log10(-1.0)-log10(-2.25) TCID/per dose. This was beside other non specific antiviral substances exhibited virus neutralizing activity. Only 3 (50%) of the 6 vaccine vials tested had virus titers of log10(-3.25) to log10(-3.5), which fell above the cut-off point recommended by the World Health Organization for measles vaccines. The sero-conversion rate of 68.6% observed among vaccinees is far lower than the immunity level of 95% required stopping measles transmission in an endemic community. Failure of 31.4% of these infants to sero-convert post vaccination can be attributed partly to administration of sub-potent vaccines. There is need for improvement and maintenance of effective vaccine cold chain system in Nigeria. There is need also for periodic monitoring of post-vaccination antibody titers as well as vaccine potency status in order to ensure development of protective seroconversion rates.

Entities:  

Keywords:  Nigeria; developing countries; immunization; infants; measles vaccine; potency; sero-conversion

Mesh:

Substances:

Year:  2015        PMID: 24825255     DOI: 10.1080/15321819.2014.920713

Source DB:  PubMed          Journal:  J Immunoassay Immunochem        ISSN: 1532-1819


  5 in total

Review 1.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

2.  Thermostability of Measles and Rubella Vaccines in a Microneedle Patch.

Authors:  Jessica C Joyce; Marcus L Collins; Paul A Rota; Mark R Prausnitz
Journal:  Adv Ther (Weinh)       Date:  2021-07-28

3.  Descriptive epidemiology of measles surveillance data, Osun state, Nigeria, 2016-2018.

Authors:  Folajimi O Shorunke; Oluwatoyin Adeola-Musa; Aisha Usman; Celestine Ameh; Endie Waziri; Stephen A Adebowale
Journal:  BMC Public Health       Date:  2019-12-04       Impact factor: 3.295

4.  Measles and rubella immunity in the population of Bhutan, 2017.

Authors:  Sonam Wangchuk; Francisco Nogareda; Namgay Tshering; Lekey Khandu; Sonam Pelden; Kathleen Wannemuehler; Sonam Wangdi; Ugyen Wangchuk; Mick Mulders; Tshewang Tamang; Minal K Patel
Journal:  Vaccine       Date:  2019-09-06       Impact factor: 3.641

5.  Prevalence of measles in vaccinated and non-vaccinated children.

Authors:  Muhammad Asif Zahoor; Muhammad Hidayat Rasool; Muhammad Waseem; Bilal Aslam; Muhammad Kashif Zahoor; Muhammad Saqalein; Zeeshan Nawaz; Rabia Sahar
Journal:  EXCLI J       Date:  2015-04-01       Impact factor: 4.068

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.